ES2525029T3 - Predicción del riesgo de sufrir episodios cardíacos adversos graves - Google Patents
Predicción del riesgo de sufrir episodios cardíacos adversos graves Download PDFInfo
- Publication number
- ES2525029T3 ES2525029T3 ES13179055.2T ES13179055T ES2525029T3 ES 2525029 T3 ES2525029 T3 ES 2525029T3 ES 13179055 T ES13179055 T ES 13179055T ES 2525029 T3 ES2525029 T3 ES 2525029T3
- Authority
- ES
- Spain
- Prior art keywords
- macers
- subject
- treatment
- risk
- compared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Medical Informatics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Primary Health Care (AREA)
- Epidemiology (AREA)
- Databases & Information Systems (AREA)
- Data Mining & Analysis (AREA)
- Endocrinology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Electrotherapy Devices (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
Abstract
Un método para seleccionar un tratamiento para un sujeto, método que comprende: la determinación de una puntuación de riesgo de sufrir un episodio cardíaco adverso grave (MACERS) para un sujeto basándose, al menos en parte, en la relación de un segundo nivel de gen soluble 2 expresado por estimulación del crecimiento (ST2) en el sujeto en un segundo momento (ST2 T1) con un primer nivel de ST2 soluble en el sujeto en un primer momento (ST2 T0), junto con un logaritmo natural ponderado de un nivel de la prohormona N-terminal del péptido natriurético de tipo cerebral (NT-proBNP) en el sujeto en un segundo momento (NP T1) de acuerdo con la siguiente fórmula: MACERS >= (ST2 T1/ST2 T0 + αln(NP T1), donde α es un factor de ponderación; la comparación de la MACERS con una MACERS de referencia; y la elección de: (a) hospitalización inicial, tratamiento continuo sobre pacientes hospitalizados o cateterismo cardíaco para un sujeto con una MACERS elevada en comparación con la MACERS de referencia, (2) un tratamiento alternativo para un sujeto que recibe un tratamiento y que presenta una MACERS elevada en comparación con la MACERS de referencia, o (3) tratamiento continuo o interrupción del tratamiento, tal como con el alta del hospital, para un sujeto que recibe un tratamiento y que presenta una MACERS disminuida en comparación con la MACERS de referencia.
Description
E13179055
26-11-2014
5
10
15
20
25
[0074] Para definir mejor la utilidad funcional de la relación ST2 combinado con un valor NT-proBNP se desarrolló una fórmula:
[0075] Esta fórmula se desarrolló evaluando el resultado como una función ABC ROC para un intervalo de coeficientes asociados con el término NT-proBNP. El resultado de esta serie de cálculos se muestra en la Figura
1.
[0076] El valor ABC máximo se consiguió con un coeficiente para a de 0,33 resultando en que la ecuación final es:
[0077] Al utilizar este algoritmo en una serie de cálculos comparando la sensibilidad, especificidad y riesgo relativo (eje lateral derecho) obtenemos el gráfico de la Figura 2.
[0078] En este gráfico el valor de puntuación que resulta en el máximo valor de riesgo relativo es 3,2. El análisis ROC de estos datos confirma que el valor de umbral óptimo es 3,3, ilustrado en la Figura 3. Además cabe destacar que el valor ABC utilizando esta puntuación es de 0,80 según se compara con el 0,77 para la relación ST2 y 0,72 para la relación NT-proBNP, que generó los siguientes valores ABC más altos.
[0079] Cuando se utiliza esta puntuación, en el valor de umbral de 3,2, para estratificar a los pacientes en esta cohorte que están en riesgo de padecer un episodio: un ingreso, un trasplante o la mortalidad, se consigue una clara distinción entre los pacientes con riesgo bajo y los pacientes con riesgo alto. Estos resultados se ilustran en la Tabla 4.
Tabla 4: Resumen de la estratificación de pacientes por el riesgo de sufrir episodios adversos en 1 año utilizando un punto de corte de la puntuación de 3,2.
Puntuación mediana
media
<3,2 >3,2 3,55 3,71
N 17 31
Episodio N 3 23
% Episodio 17,6 %
74,2 %
PPV
74,2 % NPV 82,4 %
RR 4,2
[0080] Al comparar directamente estos resultados con los resultados que utilizan sólo la relación ST2, mostrados en la Tabla 2, se ilustra que combinando la relación ST2 con un valor NT-proBNP todos los parámetros relevantes que representan la evaluación de predicción del riesgo son más fuertes; PPV, NPV y RR.
[0081] Para comparar los resultados de estratificación para el siguiente valor más fuerte, la relación NT-proBNP se resume en la Tabla 5. Los valores que utilizan la relación NT-proBNP son mucho más bajos que cuando se utiliza la relación ST2 o desde la fórmula que combina ST2 con NT-proBNP
Tabla 5: Resumen de la estratificación de pacientes por el riesgo de sufrir episodios adversos en 1 año utilizando la relación NT-proBNP
- Relación NT-proBNP mediana media
- <0,75 >0,75 0,74 0,83
- N
- 24 24
- Episodio N
- 10 16
- % Episodio
- 41,7 % 66,7 %
- PPV
- 66,7 %
- NPV
- 58,3 %
- 12
E13179055
26-11-2014
[0103] El valor óptimo ROC a partir de este análisis fue 3,52. Como observamos utilizando los datos de la cohorte de péptidos (véase el Ejemplo I), la ROC de la fórmula de puntuación de riesgo de MACE óptima también fue 3,5 pero la mejor precisión de pronóstico (mortalidad) se alcanzó con un valor 3,2 en esa cohorte. Un diagrama de caja y bigotes básico (Figura 19) muestra una resolución clara entre el grupo de supervivientes y de
20 fallecidos, p<0,0001. Para comparar, un análisis de gráfico de caja y bigotes de ST2 R L:F es similar, con un p=0,0001 (Figura 20). También se observó utilizando los datos de la cohorte de péptidos que un análisis de matriz básico y un cálculo de riesgo relativo confirman que la puntuación de riesgo de MACE proporciona la predicción de mortalidad más precisa.
Tabla 16: Análisis de matriz y riesgo relativo de las variables de predicción de mortalidad más fuertes
25
30
- ST2 R L:F
- NTproBNP R L:F Puntuación de riesgo MACE
- <0,85
- ≥0,85 <0,7 ≥0,7 <3,5 ≥3,5
- N
- 76 31 49 58 65 42
- N mortalidad
- 3 10 2 11 1 12
- % mortalidad
- 3,9% 32,3% 4,1% 19,0% 1,5% 28,6%
- PPV
- 32,3% 19,0% 28,6%
- NPV
- 96,1 % 95,9% 98,5%
- RR
- 8,2 4,6 18,6
[0104] Pese a que tanto la relación ST2 como la relación NTproBNP produjeron buenos valores de riesgo relativo, el riesgo relativo utilizando la puntuación de riesgo de MACE fue mucho mayor.
[0105] Según se determinó utilizando los datos de la cohorte de péptidos (Ejemplo 1) la fórmula de puntuación de riesgo de MACE descrita en el presente documento proporciona la mayor precisión de pronóstico, específicamente cuando el parámetro resultante es la mortalidad, según se determina por la ROC, la relación de riesgo y el cálculo de riesgo relativo. Existe una pequeña pero significativa diferencia entre los valores de umbral
17
Claims (1)
-
imagen1 imagen2
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4615808P | 2008-04-18 | 2008-04-18 | |
US46158P | 2008-04-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2525029T3 true ES2525029T3 (es) | 2014-12-16 |
Family
ID=41199760
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES13179055.2T Active ES2525029T3 (es) | 2008-04-18 | 2009-04-17 | Predicción del riesgo de sufrir episodios cardíacos adversos graves |
ES14177846.4T Active ES2590213T3 (es) | 2008-04-18 | 2009-04-17 | Predicción del riesgo a sufrir episodios cardíacos adversos graves |
ES09731842.2T Active ES2443125T3 (es) | 2008-04-18 | 2009-04-17 | Predicción del riesgo a sufrir episodios cardíacos adversos graves |
ES16166093.1T Active ES2687401T3 (es) | 2008-04-18 | 2009-04-17 | Predicción del riesgo a sufrir episodios cardíacos adversos graves |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES14177846.4T Active ES2590213T3 (es) | 2008-04-18 | 2009-04-17 | Predicción del riesgo a sufrir episodios cardíacos adversos graves |
ES09731842.2T Active ES2443125T3 (es) | 2008-04-18 | 2009-04-17 | Predicción del riesgo a sufrir episodios cardíacos adversos graves |
ES16166093.1T Active ES2687401T3 (es) | 2008-04-18 | 2009-04-17 | Predicción del riesgo a sufrir episodios cardíacos adversos graves |
Country Status (14)
Country | Link |
---|---|
US (5) | US8090562B2 (es) |
EP (5) | EP3093663B1 (es) |
JP (6) | JP5526122B2 (es) |
AU (3) | AU2009236109B2 (es) |
CA (1) | CA2720674A1 (es) |
DK (4) | DK2827152T3 (es) |
ES (4) | ES2525029T3 (es) |
HK (3) | HK1152750A1 (es) |
HR (2) | HRP20131100T1 (es) |
HU (2) | HUE029880T2 (es) |
PL (4) | PL2269063T3 (es) |
PT (4) | PT2827152T (es) |
SI (4) | SI2827152T1 (es) |
WO (1) | WO2009129454A2 (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002038794A2 (en) | 2000-11-09 | 2002-05-16 | The Brigham And Women's Hospital, Inc. | Cardiovascular disease diagnostic and therapeutic targets |
PT3072978T (pt) | 2002-05-09 | 2018-10-15 | Brigham & Womens Hospital Inc | 1l1rl-1 como um marcador de doença cardiovascular |
ES2646142T3 (es) | 2006-04-24 | 2017-12-12 | Critical Care Diagnostics, Inc. | Evaluación de la eficacia de un tratamiento en un sujeto en función de los niveles de ST2 |
WO2007143295A2 (en) * | 2006-04-27 | 2007-12-13 | Critical Care Diagnostics, Inc. | Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease |
DK2021796T3 (da) | 2006-05-01 | 2012-05-29 | Critical Care Diagnostics Inc | Diagnose af hjerte-kar-sygdom |
DK2019965T3 (en) * | 2006-05-02 | 2015-07-20 | Critical Care Diagnostics Inc | DIFFERENTIAL BETWEEN LUNG AND Cardiovascular Disease |
US9968266B2 (en) | 2006-12-27 | 2018-05-15 | Cardiac Pacemakers, Inc. | Risk stratification based heart failure detection algorithm |
SI2827152T1 (sl) | 2008-04-18 | 2016-10-28 | Critical Care Diagnostics,Inc. | Napovedovanje tveganja večjih neželenih srčno-žilnih dogodkov |
EP2353011B1 (en) * | 2008-10-07 | 2020-03-04 | B.R.A.H.M.S GmbH | Biomarker for the prediction of first adverse events |
US9561006B2 (en) * | 2008-10-15 | 2017-02-07 | The United States Of America As Represented By The Secretary Of The Navy | Bayesian modeling of pre-transplant variables accurately predicts kidney graft survival |
US8417541B1 (en) * | 2009-08-27 | 2013-04-09 | Cerner Innovation, Inc. | Multi-stage model for predicting probabilities of mortality in adult critically ill patients |
JP5730879B2 (ja) * | 2009-09-25 | 2015-06-10 | ヴォルケイノウ・コーポレーション | 確認された生理学的パラメータに基づいて患者が臨床事象または臨床的無症状事象を有する可能性を決定するデバイスおよびシステム |
RU2625014C2 (ru) | 2010-04-09 | 2017-07-11 | Критикал Кэа Дайэгностикс, Инк. | Антитела против растворимого st-2 человека и способы анализа |
US10943676B2 (en) | 2010-06-08 | 2021-03-09 | Cerner Innovation, Inc. | Healthcare information technology system for predicting or preventing readmissions |
US8728742B2 (en) | 2011-03-17 | 2014-05-20 | Critical Care Diagnostics, Inc. | Methods predicting risk of an adverse clinical outcome |
JP6134316B2 (ja) | 2011-07-18 | 2017-05-24 | クリティカル ケア ダイアグノスティクス インコーポレイテッド | 心臓血管疾患を治療する方法および運動療法の有効性を予測する方法 |
EP2637023A1 (en) * | 2012-03-08 | 2013-09-11 | B.R.A.H.M.S GmbH | Prediction of outcome in patients with chronic obstructive pulmonary disease |
EP3434260A1 (en) * | 2012-05-18 | 2019-01-30 | Critical Care Diagnostics, Inc. | Methods for treating or predicting risk of ventricular tachyarrhythmia event |
CN102830234A (zh) * | 2012-08-10 | 2012-12-19 | 杭州华得森生物技术有限公司 | 一种检测人心力衰竭新型标志物st2的快速诊断试剂盒 |
RU2019107598A (ru) | 2012-08-16 | 2019-03-28 | Критикал Кэа Дайэгностикс, Инк. | Способы прогнозирования риска развития гипертензии |
RU2015110054A (ru) * | 2012-08-21 | 2016-10-10 | Критикал Кэа Дайэгностикс, Инк. | Мультимаркерная стратификация риска |
RU2510505C1 (ru) * | 2012-11-15 | 2014-03-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Тверская государственная медицинская академия" Министерства здравоохранения Российской Федерации | Способ определения вероятности выраженной сердечной недостаточности в клинической картине инфаркта миокарда |
GB201310290D0 (en) * | 2013-06-10 | 2013-07-24 | Univ Manchester | Method for determining a probability of a major adverse cardiac event (MACE) |
CN106461636A (zh) * | 2014-01-10 | 2017-02-22 | 重症监护诊断股份有限公司 | 用于测定心力衰竭风险的方法和系统 |
US10670611B2 (en) | 2014-09-26 | 2020-06-02 | Somalogic, Inc. | Cardiovascular risk event prediction and uses thereof |
US10079073B2 (en) | 2014-12-11 | 2018-09-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
US10324089B2 (en) | 2014-12-11 | 2019-06-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
US20160256064A1 (en) * | 2015-03-02 | 2016-09-08 | Edward Harvey Estes, JR. | Method and device to predict adverse cardiovascular events and mortality from an electrocardiogram-based validated risk score |
WO2017172755A1 (en) * | 2016-04-01 | 2017-10-05 | Cardiac Pacemakers, Inc. | Multi-disease patient management |
AT518560B1 (de) | 2016-04-18 | 2018-01-15 | Trumpf Maschinen Austria Gmbh & Co Kg | Biegebalken für eine Schwenkbiegemaschine |
EP3614908A1 (en) | 2017-04-29 | 2020-03-04 | Cardiac Pacemakers, Inc. | Heart failure event rate assessment |
JP7057995B2 (ja) | 2017-10-03 | 2022-04-21 | 株式会社国際電気通信基礎技術研究所 | 哺乳動物におけるうつ病の病態プロファイルを検出するバイオマーカーとその利用 |
US20200074313A1 (en) * | 2018-08-29 | 2020-03-05 | Koninklijke Philips N.V. | Determining features to be included in a risk assessment instrument |
JP7043374B2 (ja) | 2018-09-18 | 2022-03-29 | 株式会社日立製作所 | 多機能神経フィードバックシステム及び多機能神経フィードバック方法 |
US11446009B2 (en) | 2018-12-11 | 2022-09-20 | Eko.Ai Pte. Ltd. | Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images |
US11931207B2 (en) | 2018-12-11 | 2024-03-19 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device |
US12001939B2 (en) | 2018-12-11 | 2024-06-04 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views |
US11551817B2 (en) | 2020-01-14 | 2023-01-10 | International Business Machines Corporation | Assessing unreliability of clinical risk prediction |
EP4057010A3 (en) * | 2021-03-08 | 2023-01-18 | Sanofi | Cardiovascular disease |
Family Cites Families (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4208479A (en) | 1977-07-14 | 1980-06-17 | Syva Company | Label modified immunoassays |
US5206140A (en) | 1988-06-24 | 1993-04-27 | Research Corporation Technologies, Inc. | Assay for soluble crosslinked fibrin polymers |
US5217899A (en) | 1990-08-24 | 1993-06-08 | The General Hospital Corporation | Cell stretching apparatus |
JP2665850B2 (ja) | 1991-11-14 | 1997-10-22 | 塩野義製薬株式会社 | hBNPのC端を認識するモノクロ−ナル抗体 |
GB9211686D0 (en) | 1992-06-03 | 1992-07-15 | Medisinsk Innovation A S | Chemical compounds |
JP2732005B2 (ja) | 1992-12-14 | 1998-03-25 | 眞一 富永 | ヒトst2をコードするdna、該dnaの発現産物、該dnaを発現させることによる発現産物の製造方法 |
JPH0731479A (ja) | 1993-02-23 | 1995-02-03 | Shinichi Tominaga | マウスst2lをコードするdna、該dnaの発現産物、該dnaを発現させることによる発現産物の製造方法 |
US6066322A (en) | 1995-03-03 | 2000-05-23 | Millennium Pharmaceuticals, Inc. | Methods for the treatment of immune disorders |
WO1998007754A1 (en) | 1996-08-23 | 1998-02-26 | Human Genome Sciences, Inc. | T1 receptor-like ligand ii |
EP0981619A1 (en) | 1997-02-28 | 2000-03-01 | Human Genome Sciences, Inc. | T1/st2-receptor ligand iii |
DE19711932A1 (de) | 1997-03-21 | 1998-09-24 | Anne Katrin Dr Werenskiold | In vitro-Verfahren zum Prognostizieren des Krankheitsverlaufs von Patienten mit Mammakarzinom und/oder zum Diagnostizieren eines Mammakarzinoms |
PT1493439E (pt) | 1997-04-02 | 2012-01-10 | Brigham & Womens Hospital | Meio de avaliação do perfil de risco de um indivíduo para uma doença aterosclerótica |
ATE489633T1 (de) | 1997-06-10 | 2010-12-15 | Lpath Inc | Verfahren zum frühzeitigen nachweis herzerkrankungen |
JP3516655B2 (ja) | 1997-09-11 | 2004-04-05 | 塩野義製薬株式会社 | Bnpの免疫測定法 |
GB9727172D0 (en) | 1997-12-24 | 1998-02-25 | Univ Glasgow | Reagents specific for st2l and uses therefor |
US6309888B1 (en) | 1998-09-04 | 2001-10-30 | Leuven Research & Development Vzw | Detection and determination of the stages of coronary artery disease |
GB9827348D0 (en) * | 1998-12-12 | 1999-02-03 | Univ Leicester | Natriuretic peptide |
AU2055300A (en) | 1998-12-18 | 2000-07-03 | Scios Inc. | Methods for detection and use of differentially expressed genes in disease states |
AU5309600A (en) | 1999-06-02 | 2000-12-18 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the treatment and diagnosis of immune disorders |
FR2795823B1 (fr) | 1999-07-01 | 2001-11-23 | Inst Nat Sante Rech Med | Methodes et kits pour le diagnostic ou le suivi d'une pathologie synoviale ou osteoarticulaire comprenant l'utilisation d'un marqueur specifique de la degradation du tissu synovial |
CA2383252A1 (en) | 1999-08-24 | 2001-03-01 | Medicure International Inc. | Treatment of cardiovascular related pathologies |
US6323334B1 (en) | 1999-09-24 | 2001-11-27 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding a 103 gene product and uses therefor |
AU2001218871A1 (en) | 2000-03-21 | 2001-10-03 | Takao Arai | Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same |
FR2807170B1 (fr) | 2000-03-30 | 2002-06-28 | Sipal | Charniere elastique a frottement reduit |
JP2004506443A (ja) | 2000-08-22 | 2004-03-04 | ブライハム アンド ウィメンズ ホスピタル インコーポレーテッド | 心血管状態の診断および処置 |
WO2002038794A2 (en) | 2000-11-09 | 2002-05-16 | The Brigham And Women's Hospital, Inc. | Cardiovascular disease diagnostic and therapeutic targets |
US6537221B2 (en) | 2000-12-07 | 2003-03-25 | Koninklijke Philips Electronics, N.V. | Strain rate analysis in ultrasonic diagnostic images |
FI20010019A (fi) | 2001-01-05 | 2002-07-06 | Biohit Oyj | Menetelmä atrofisen diagnostisoimiseksi |
US20040253637A1 (en) | 2001-04-13 | 2004-12-16 | Biosite Incorporated | Markers for differential diagnosis and methods of use thereof |
US7713705B2 (en) | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
EP1666881B1 (en) | 2001-05-04 | 2010-02-17 | Biosite Incorporated | Diagnostic markers of acute coronary syndromes and methods of use thereof |
US6905827B2 (en) | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
WO2003022987A2 (en) | 2001-07-26 | 2003-03-20 | Eos Biotechnology, Inc. | Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection |
US6810284B1 (en) | 2001-11-21 | 2004-10-26 | Pacesetter, Inc. | Implantable cardiac stimulation system and method for monitoring diastolic function |
PT3072978T (pt) | 2002-05-09 | 2018-10-15 | Brigham & Womens Hospital Inc | 1l1rl-1 como um marcador de doença cardiovascular |
AU2003239544A1 (en) | 2002-05-24 | 2003-12-12 | Tularik Inc. | Amplification and overexpression of oncogenes |
US8263325B2 (en) | 2002-11-15 | 2012-09-11 | Ottawa Heart Institute Research Corporation | Predicting, detecting and monitoring treatment of cardiomyopathies and myocarditis |
CA2507415A1 (en) * | 2002-11-21 | 2004-06-03 | The University Of Leicester | Bodily fluid markers of tissue hypoxia |
US20070042978A1 (en) | 2002-12-19 | 2007-02-22 | Jean-Philippe Girard | Nf-hev compositions and methods of use |
US20040133079A1 (en) | 2003-01-02 | 2004-07-08 | Mazar Scott Thomas | System and method for predicting patient health within a patient management system |
US20040220155A1 (en) | 2003-03-28 | 2004-11-04 | Pharmacia Corporation | Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith |
US20060257558A1 (en) | 2003-10-31 | 2006-11-16 | Hiroshi Nomura | Plasma polymerization of atomically modified surfaces |
EP1711622A2 (en) | 2003-11-26 | 2006-10-18 | Applera Corporation | Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof |
WO2005055810A2 (en) | 2003-12-05 | 2005-06-23 | The Cleveland Clinic Foundation | Risk markers for cardiovascular disease |
US20050196817A1 (en) | 2004-01-20 | 2005-09-08 | Molecular Staging Inc. | Biomarkers for sepsis |
NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
JP2005291899A (ja) | 2004-03-31 | 2005-10-20 | Akira Matsumori | 心疾患の検査法 |
EP1833766A1 (en) | 2004-12-17 | 2007-09-19 | Clearwater Systems Corp. | Method and apparatus for treating fluids |
EP1849009B1 (en) | 2005-01-24 | 2008-10-29 | F. Hoffmann-La Roche AG | The use of cardiac hormones for assessing a cardiovascular risk with respect to the administration of anti-inflammatory drugs. |
EP1731910A1 (en) * | 2005-06-07 | 2006-12-13 | F. Hoffmann-La Roche Ag | Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases |
US20070021977A1 (en) | 2005-07-19 | 2007-01-25 | Witt Biomedical Corporation | Automated system for capturing and archiving information to verify medical necessity of performing medical procedure |
JP4820192B2 (ja) | 2006-03-17 | 2011-11-24 | 一般財団法人化学及血清療法研究所 | 急性冠症候群でのadamts13の測定と利用 |
ES2646142T3 (es) * | 2006-04-24 | 2017-12-12 | Critical Care Diagnostics, Inc. | Evaluación de la eficacia de un tratamiento en un sujeto en función de los niveles de ST2 |
WO2007143295A2 (en) | 2006-04-27 | 2007-12-13 | Critical Care Diagnostics, Inc. | Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease |
DK2021796T3 (da) | 2006-05-01 | 2012-05-29 | Critical Care Diagnostics Inc | Diagnose af hjerte-kar-sygdom |
DK2019965T3 (en) | 2006-05-02 | 2015-07-20 | Critical Care Diagnostics Inc | DIFFERENTIAL BETWEEN LUNG AND Cardiovascular Disease |
US8147817B2 (en) | 2006-05-04 | 2012-04-03 | The Brigham And Women's Hospital, Inc. | IL-33 in the treatment and diagnosis of diseases and disorders |
EP2030025A2 (en) * | 2006-06-07 | 2009-03-04 | Tethys Bioscience, Inc. | Markers associated with arteriovascular events and methods of use thereof |
RU2312591C1 (ru) | 2006-06-14 | 2007-12-20 | Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Федерального агентства по здравоохранению и социальному развитию" | Способ прогнозирования развития риска внезапной смерти у больных с лево- и правожелудочковой экстрасистолией |
US20080233191A1 (en) | 2007-03-22 | 2008-09-25 | Brent Blackburn | Use of ranolazine for elevated brain-type natriuretic peptide |
US20090111708A1 (en) | 2007-05-11 | 2009-04-30 | Seddon Johanna M | Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk |
GB0713404D0 (en) | 2007-07-11 | 2007-08-22 | Integra Sp Ipr Ltd | Altio graph |
US20100267062A1 (en) | 2007-09-26 | 2010-10-21 | Norbert Frey | Osteopontin as Novel Prognostic Biomarker for Heart Failure |
FR2923029B1 (fr) | 2007-10-26 | 2009-11-20 | Minima | Lunettes de type sans entourage a branches filaires |
SI2827152T1 (sl) | 2008-04-18 | 2016-10-28 | Critical Care Diagnostics,Inc. | Napovedovanje tveganja večjih neželenih srčno-žilnih dogodkov |
WO2010025393A2 (en) * | 2008-08-28 | 2010-03-04 | The Regents Of The University Of California | Protein biomarkers and methods for diagnosing kawasaki disease |
WO2010054810A1 (en) | 2008-11-11 | 2010-05-20 | B.R.A.H.M.S Ag | Prognosis and risk assessment in patients suffering from heart failure by determining the level of adm and bnp |
BR112012011230A2 (pt) | 2009-11-13 | 2016-04-05 | Bg Medicine Inc | fatores de risco e previsão de infarto do miocárdio |
US8258456B2 (en) | 2009-11-27 | 2012-09-04 | Himax Imaging, Inc. | Image sensor |
RU2625014C2 (ru) | 2010-04-09 | 2017-07-11 | Критикал Кэа Дайэгностикс, Инк. | Антитела против растворимого st-2 человека и способы анализа |
RU2618437C2 (ru) | 2010-11-01 | 2017-05-03 | Б.Р.А.Х.М.С Гмбх | Оценка прогноза и риска пациентов с неспецифическими жалобами |
RU2452394C1 (ru) | 2010-11-09 | 2012-06-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Ульяновский государственный университет | Способ прогнозирования риска смерти больных хронической сердечной недостаточностью |
US8728742B2 (en) | 2011-03-17 | 2014-05-20 | Critical Care Diagnostics, Inc. | Methods predicting risk of an adverse clinical outcome |
US8615387B2 (en) * | 2011-04-07 | 2013-12-24 | Invensys Systems, Inc. | Dynamic simulation of fluid filled vessels |
JP6134316B2 (ja) | 2011-07-18 | 2017-05-24 | クリティカル ケア ダイアグノスティクス インコーポレイテッド | 心臓血管疾患を治療する方法および運動療法の有効性を予測する方法 |
EP3434260A1 (en) | 2012-05-18 | 2019-01-30 | Critical Care Diagnostics, Inc. | Methods for treating or predicting risk of ventricular tachyarrhythmia event |
RU2019107598A (ru) * | 2012-08-16 | 2019-03-28 | Критикал Кэа Дайэгностикс, Инк. | Способы прогнозирования риска развития гипертензии |
RU2015110054A (ru) | 2012-08-21 | 2016-10-10 | Критикал Кэа Дайэгностикс, Инк. | Мультимаркерная стратификация риска |
US9665593B2 (en) * | 2013-03-28 | 2017-05-30 | International Business Machines Corporation | Dynamically synching elements in file |
JP6178687B2 (ja) | 2013-09-27 | 2017-08-09 | 富士機械工業株式会社 | グラビア塗工装置 |
CN106461636A (zh) | 2014-01-10 | 2017-02-22 | 重症监护诊断股份有限公司 | 用于测定心力衰竭风险的方法和系统 |
USD770057S1 (en) | 2014-04-14 | 2016-10-25 | Critical Care Diagnostics, Inc. | Blood test kit |
US9934249B2 (en) | 2014-06-03 | 2018-04-03 | Conduent Business Machines Services, Llc | Systems and methods for context-aware and personalized access to visualizations of road events |
USD800332S1 (en) | 2014-09-23 | 2017-10-17 | Critical Care Diagnostics, Inc. | Blood test kit |
USD800333S1 (en) | 2014-09-23 | 2017-10-17 | Critical Care Diagnostics, Inc. | Blood test kit |
US10324089B2 (en) | 2014-12-11 | 2019-06-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
US10079073B2 (en) | 2014-12-11 | 2018-09-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
-
2009
- 2009-04-17 SI SI200931469A patent/SI2827152T1/sl unknown
- 2009-04-17 ES ES13179055.2T patent/ES2525029T3/es active Active
- 2009-04-17 HU HUE14177846A patent/HUE029880T2/en unknown
- 2009-04-17 HU HUE16166093A patent/HUE039963T2/hu unknown
- 2009-04-17 CA CA2720674A patent/CA2720674A1/en not_active Abandoned
- 2009-04-17 SI SI200931872T patent/SI3093663T1/sl unknown
- 2009-04-17 PL PL09731842T patent/PL2269063T3/pl unknown
- 2009-04-17 PL PL13179055T patent/PL2660599T3/pl unknown
- 2009-04-17 SI SI200931045T patent/SI2660599T1/sl unknown
- 2009-04-17 PL PL16166093T patent/PL3093663T3/pl unknown
- 2009-04-17 EP EP16166093.1A patent/EP3093663B1/en active Active
- 2009-04-17 ES ES14177846.4T patent/ES2590213T3/es active Active
- 2009-04-17 DK DK14177846.4T patent/DK2827152T3/en active
- 2009-04-17 PT PT141778464T patent/PT2827152T/pt unknown
- 2009-04-17 AU AU2009236109A patent/AU2009236109B2/en not_active Ceased
- 2009-04-17 PL PL14177846.4T patent/PL2827152T3/pl unknown
- 2009-04-17 PT PT97318422T patent/PT2269063E/pt unknown
- 2009-04-17 EP EP14177846.4A patent/EP2827152B1/en not_active Not-in-force
- 2009-04-17 PT PT16166093T patent/PT3093663T/pt unknown
- 2009-04-17 ES ES09731842.2T patent/ES2443125T3/es active Active
- 2009-04-17 EP EP13179055.2A patent/EP2660599B1/en not_active Not-in-force
- 2009-04-17 DK DK09731842.2T patent/DK2269063T3/da active
- 2009-04-17 PT PT131790552T patent/PT2660599E/pt unknown
- 2009-04-17 WO PCT/US2009/040941 patent/WO2009129454A2/en active Application Filing
- 2009-04-17 EP EP09731842.2A patent/EP2269063B1/en not_active Not-in-force
- 2009-04-17 SI SI200930776T patent/SI2269063T1/sl unknown
- 2009-04-17 JP JP2011505224A patent/JP5526122B2/ja not_active Expired - Fee Related
- 2009-04-17 DK DK16166093.1T patent/DK3093663T3/en active
- 2009-04-17 EP EP18166387.3A patent/EP3378955A1/en not_active Withdrawn
- 2009-04-17 DK DK13179055.2T patent/DK2660599T3/en active
- 2009-04-17 ES ES16166093.1T patent/ES2687401T3/es active Active
- 2009-04-17 US US12/425,956 patent/US8090562B2/en active Active
-
2011
- 2011-07-04 HK HK11106781.7A patent/HK1152750A1/xx not_active IP Right Cessation
- 2011-07-04 HK HK13112822.4A patent/HK1185658A1/xx not_active IP Right Cessation
- 2011-11-18 US US13/299,612 patent/US20120065897A1/en not_active Abandoned
-
2013
- 2013-03-06 US US13/787,137 patent/US9886553B2/en not_active Expired - Fee Related
- 2013-11-20 HR HRP20131100AT patent/HRP20131100T1/hr unknown
-
2014
- 2014-04-03 US US14/244,526 patent/US9965593B2/en active Active
- 2014-04-14 JP JP2014082442A patent/JP5873521B2/ja not_active Expired - Fee Related
- 2014-11-03 HR HRP20141056AT patent/HRP20141056T1/hr unknown
-
2015
- 2015-07-17 HK HK15106822.4A patent/HK1206419A1/xx not_active IP Right Cessation
-
2016
- 2016-01-15 JP JP2016006007A patent/JP6200975B2/ja not_active Expired - Fee Related
- 2016-02-04 AU AU2016200697A patent/AU2016200697B2/en not_active Ceased
-
2017
- 2017-08-28 JP JP2017162932A patent/JP6484679B2/ja not_active Expired - Fee Related
-
2018
- 2018-04-04 AU AU2018202350A patent/AU2018202350A1/en not_active Abandoned
- 2018-04-12 US US15/951,376 patent/US11170896B2/en active Active
-
2019
- 2019-02-18 JP JP2019026401A patent/JP6788050B2/ja active Active
-
2020
- 2020-10-29 JP JP2020181010A patent/JP2021039108A/ja not_active Ceased
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2525029T3 (es) | Predicción del riesgo de sufrir episodios cardíacos adversos graves | |
Amar et al. | A brain natriuretic peptide-based prediction model for atrial fibrillation after thoracic surgery: development and internal validation | |
Panagopoulou et al. | NTproBNP: an important biomarker in cardiac diseases | |
Weissler-Snir et al. | Prevention of sudden death in hypertrophic cardiomyopathy: bridging the gaps in knowledge | |
Klaar et al. | Prognostic value of serial B‐type natriuretic peptide measurement in asymptomatic organic mitral regurgitation | |
Hallbergson et al. | Right ventricular remodeling after pulmonary valve replacement: early gains, late losses | |
Volpe et al. | Prediction of long‐term survival in chronic heart failure by multiple biomarker assessment: A 15‐year prospective follow‐up study | |
Seligman et al. | Comparing the accuracy of predictors of mortality in ventilator-associated pneumonia | |
Tycinska et al. | The value of apelin-36 and brain natriuretic peptide measurements in patients with first ST-elevation myocardial infarction | |
ES2399931T3 (es) | Diagnóstico y estratificación de riesgo del síndrome coronario agudo mediante CT-proET-1 en combinación con NTproBNP | |
ES2440740T3 (es) | Utilización de SLIM-1 en la evaluación de la insuficiencia cardiaca | |
Roubille et al. | Routinely-feasible multiple biomarkers score to predict prognosis after revascularized STEMI | |
Schuster et al. | Fast manual long-axis strain assessment provides optimized cardiovascular event prediction following myocardial infarction | |
Glezeva et al. | Heart failure in sub‐Saharan Africa: review of the aetiology of heart failure and the role of point‐of‐care biomarker diagnostics | |
Torii et al. | Updated left ventricular diastolic function recommendations and cardiovascular events in patients with heart failure hospitalization | |
Ait Ali et al. | Left ventricular dysfunction in repaired tetralogy of Fallot: incidence and impact on atrial arrhythmias at long term-follow up | |
Abbate et al. | Right ventricular cardiomyocyte apoptosis in patients with acute myocardial infarction of the left ventricular wall | |
Seoudy et al. | HFA‐PEFF score: prognosis in patients with preserved ejection fraction after transcatheter aortic valve implantation | |
Topilsky et al. | When to intervene for asymptomatic mitral valve regurgitation | |
Bäck et al. | Biomarkers in mitral regurgitation | |
Maewal et al. | Natriuretic peptide hormone measurement in acute coronary syndromes | |
Harrington et al. | Impact of pulmonary valve replacement on left ventricular rotational mechanics in repaired tetralogy of Fallot | |
Kim et al. | Impact of genetic insights into mendelian disease on cardiovascular clinical practice | |
Meredith et al. | Strain assessment in aortic stenosis: pathophysiology and clinical utility | |
Ashley et al. | Brain natriuretic peptides as biomarkers for atherosclerosis |